Rafael (RFL) 10-Q 5 Mar 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jan. 31, 2020	Mar. 02, 2020
Entity Registrant Name	Rafael Holdings, Inc.
Entity Central Index Key	0001713863
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Document Type	10-Q
Document Period End Date	Jan. 31, 2020
Document Fiscal Period Focus	Q2
Entity Shell Company	false
Document Fiscal Year Focus	2020
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	000-55863
Entity Interactive Data Current	Yes
Entity Incorporation State country code	DE
Class A common stock
Entity Common Stock Shares Outstanding		787,163
Class B common stock
Entity Common Stock Shares Outstanding		15,031,723

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 9,522	$ 12,024
Trade accounts receivable, net of allowance for doubtful accounts of $170 and $122 at January 31, 2020 and July 31, 2019, respectively	325	450
Due from Rafael Pharmaceuticals	118	280
Prepaid expenses and other current assets	326	507
Total current assets	10,291	13,261
Property and equipment, net	48,250	48,733
Investments - Rafael Pharmaceuticals	70,018	70,018
Investments - Other Pharmaceuticals	2,000	2,000
Investments - Hedge Funds	5,645	5,125
Deferred income tax assets, net	7	19
In-process research and development and patents	1,575	1,575
Other assets	1,450	1,412
TOTAL ASSETS	139,236	142,143
CURRENT LIABILITIES
Trade accounts payable	569	795
Accrued expenses	579	605
Other current liabilities	48	27
Total current liabilities	1,196	1,427
Due to Related Party	29	65
Convertible note, net of discount of $0 and $54 - Related Party		14,946
Other liabilities	92	292
Accrued interest on convertible note - Related Party		649
TOTAL LIABILITIES	1,317	17,379
COMMITMENTS AND CONTINGENCIES
EQUITY
Additional paid-in capital	128,843	112,898
Accumulated deficit	(8,691)	(5,840)
Accumulated other comprehensive income related to foreign currency translation adjustment	3,756	3,784
Total equity attributable to Rafael Holdings, Inc.	124,065	110,981
Noncontrolling interests	13,854	13,783
TOTAL EQUITY	137,919	124,764
TOTAL LIABILITIES AND EQUITY	139,236	142,143
Class A common stock
EQUITY
Common stock value	8	8
TOTAL EQUITY	8	8
Class B common stock
EQUITY
Common stock value	149	131
TOTAL EQUITY	$ 149	$ 131

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Allowance for doubtful accounts	$ 170	$ 122
Convertible debt, net of discount	$ 0	$ 54
Class A common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	787,163	787,163
Common stock, shares outstanding	787,163	787,163
Class B common stock
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,020,485	13,142,502
Common stock, shares outstanding	15,020,485	13,142,502

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
REVENUE:
Rental - Third Party	$ 370	$ 306	$ 716	$ 689
Rental - Related Party	527	522	1,047	1,043
Parking	219	189	443	420
Other - Related Party	120		240
Total Revenue	1,236	1,017	2,446	2,152
COSTS AND EXPENSES
Selling, general and administrative	2,221	1,716	4,262	3,169
Research and development	448	276	693	649
Depreciation and amortization	473	431	939	860
Loss from Operations	(1,906)	(1,406)	(3,448)	(2,526)
Interest income (expense), net	33	767	(31)	868
Net loss resulting from foreign exchange transactions			(5)
Gain on sales of marketable securities, net		103		330
Unrealized gain (loss) on Investments - Hedge Funds	557	(148)	520	(52)
Loss Before Income Taxes	(1,316)	(684)	(2,964)	(1,380)
(Provision for) benefit from income taxes	(12)	(17)	(16)	14
Net Loss	(1,328)	(701)	(2,980)	(1,366)
Net (loss) income attributable to noncontrolling interests	(75)	320	(129)	136
Net Loss attributable to Rafael Holdings, Inc.	(1,253)	(1,021)	(2,851)	(1,502)
OTHER COMPREHENSIVE INCOME (LOSS)
Net Loss	(1,328)	(701)	(2,980)	(1,366)
Foreign currency translation adjustments	(34)	80	(28)	2
Total Comprehensive Loss	(1,362)	(621)	(3,008)	(1,364)
Comprehensive (loss) income attributable to noncontrolling interests	(18)	15	(16)	23
Total Comprehensive Loss attributable to Rafael Holdings, Inc.	$ (1,344)	$ (636)	$ (2,992)	$ (1,387)
Loss Per Share:
Basic and diluted	$ (0.08)	$ (0.08)	$ (0.18)	$ (0.12)
Weighted average number of shared used in calculation of loss per share:
Basic and diluted	15,790,400	13,489,583	15,715,442	12,634,389

Consolidated Statements of Equi

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Common Stock, Series A	Common Stock, Series B	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
BALANCE at Jul. 31, 2018	$ 8	$ 118	$ 103,636	$ (1,108)	$ 4,043	$ 9,427	$ 116,124
BALANCE, SHARES at Jul. 31, 2018	787,163	11,762,346
Net loss				(1,502)		136	(1,366)
Adoption effect of ASU 2016-01				(39)	39
Purchase of Class B Common Shares		$ 12	8,630				8,642
Purchase of Class B Common Shares, shares		1,254,200
Stock based compensation to Board of Directors			107				107
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation		$ 1	64				65
Stock based compensation, Shares		70,718
Stock options exercised			163				163
Stock options exercised, shares		33,196
Debt discount on convertible debt			71				71
Capital contribution from noncontrolling interest						4,587	4,587
Foreign currency translation adjustment					(2)		(2)
BALANCE at Jan. 31, 2019	$ 8	$ 131	112,671	(2,649)	4,080	14,150	128,391
BALANCE, SHARES at Jan. 31, 2019	787,163	13,133,069
BALANCE at Oct. 31, 2018	$ 8	$ 118	103,784	(1,628)	4,160	9,243	115,685
BALANCE, SHARES at Oct. 31, 2018	787,163	11,786,397
Net loss				(1,021)		320	(701)
Purchase of Class B Common Shares		$ 12	8,630				8,642
Purchase of Class B Common Shares, shares		1,254,200
Stock based compensation to Board of Directors			107				107
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation		$ 1	34				35
Stock based compensation, Shares		70,718
Stock options exercised			45				45
Stock options exercised, shares		9,145
Debt discount on convertible debt			71				71
Capital contribution from noncontrolling interest						4,587	4,587
Foreign currency translation adjustment					(80)		(80)
BALANCE at Jan. 31, 2019	$ 8	$ 131	112,671	(2,649)	4,080	14,150	128,391
BALANCE, SHARES at Jan. 31, 2019	787,163	13,133,069
BALANCE at Jul. 31, 2019	$ 8	$ 131	112,898	(5,840)	3,784	13,783	124,764
BALANCE, SHARES at Jul. 31, 2019	787,163	13,142,502
Net loss				(2,851)		(129)	(2,980)
Stock based compensation to Board of Directors			208				208
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation			203				203
Stock based compensation, Shares		20,863
Shares issued for convertible debt		$ 18	15,650				15,668
Shares issued for convertible debt, shares		1,849,749
Shares withheld for payroll taxes			(116)				(116)
Shares withheld for payroll taxes, shares		(5,238)
Conversion of LipoMedix Bridge Notes						200	200
Foreign currency translation adjustment					(28)		(28)
BALANCE at Jan. 31, 2020	$ 8	$ 149	128,843	(8,691)	3,756	13,854	137,919
BALANCE, SHARES at Jan. 31, 2020	787,163	15,020,485
BALANCE at Oct. 31, 2019	$ 8	$ 149	128,642	(7,438)	3,790	13,811	138,962
BALANCE, SHARES at Oct. 31, 2019	787,163	14,997,251
Net loss				(1,253)		(75)	(1,328)
Stock based compensation to Board of Directors			208				208
Stock based compensation to Board of Directors, shares		12,609
Stock based compensation			109				109
Stock based compensation, Shares		15,863
Shares withheld for payroll taxes			(116)				(116)
Shares withheld for payroll taxes, shares		(5,238)
Conversion of LipoMedix Bridge Notes						118	118
Foreign currency translation adjustment					(34)		(34)
BALANCE at Jan. 31, 2020	$ 8	$ 149	$ 128,843	$ (8,691)	$ 3,756	$ 13,854	$ 137,919
BALANCE, SHARES at Jan. 31, 2020	787,163	15,020,485

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Operating activities
Net loss	$ (2,980)	$ (1,366)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	939	860
Deferred income taxes	12	(15)
Interest income on Series D Convertible Note		(848)
Net gain on sales of marketable securities		(330)
Unrealized (gain) loss on investments - Hedge Funds	(520)	52
Provision for doubtful accounts	48	9
Non-cash compensation	411	172
Amortization of debt discount	54	5
Change in assets and liabilities:
Trade accounts receivable	77	(78)
Prepaid expenses and other current assets	181	(186)
Other assets	(38)	(82)
Accounts payable and accrued expenses	(252)	296
Due to/from related parties	126	588
Other current liabilities		39
Other liabilities	42	(15)
Net cash used in operating activities	(1,900)	(899)
Investing activities
Purchases of property and equipment	(456)	(58)
Proceeds from sale and maturity of marketable securities, net		25,031
Investment in Rafael Pharmaceuticals		(55,870)
Net cash used in investing activities	(456)	(30,897)
Financing activities
Contribution from noncontrolling interest of consolidated entity		4,587
Repayment of Loan from Rafael Pharmaceuticals		3,300
Proceeds from exercise of options		163
Proceed from sale of shares		7,777
Proceeds from convertible notes payable - Related Party		15,000
Payments for taxes related to shares withheld for employee taxes	(116)
Net cash (used in) provided by financing activities	(116)	30,827
Effect of exchange rate changes on cash and cash equivalents	(30)	(65)
Net decrease in cash and cash equivalents	(2,502)	(1,034)
Cash and cash equivalents at beginning of period	12,024	15,803
Cash and cash equivalents at end of period	9,522	14,769
Supplemental Schedule of Non-Cash Investing and Financing Activities
Adoption effect of ASU 2016-01		39
Beneficial conversion feature of convertible debt - Related Party		71
Debt and accrued interest converted to Series D Preferred Stock		10,848
Related Party deposit utilized to purchase Class B Common Stock		864
Conversion of LipoMedix Bridge Note	200
Conversions of related party convertible notes payable and accrued interest	$ 15,668

Description of Business

Description of Business	6 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 — DESCRIPTION OF BUSINESS Rafael Holdings, Inc. ("Rafael Holdings" or the "Company"), a Delaware corporation, owns interests in commercial real estate assets and clinical stage pharmaceutical companies. The assets are operated as two separate lines of business. The commercial real estate holdings consist of a building at 520 Broad Street in Newark, New Jersey that serves as headquarters for the Company and certain affiliated entities and an associated 800-car public garage, an office/data center building in Piscataway, New Jersey and a portion of a building in Israel. The pharmaceutical holdings include preferred equity interests and a warrant to purchase additional equity interests in Rafael Pharmaceuticals, Inc., or Rafael Pharmaceuticals, which is a clinical stage, oncology-focused, pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells, and a majority equity interest in LipoMedix Pharmaceuticals Ltd., or LipoMedix, a clinical stage oncological pharmaceutical company based in Israel. In addition, we have more recently established the Barer Institute ("Barer"), a wholly-owned early stage venture focused on developing a pipeline of therapeutic compounds, including compounds to regulate cancer metabolism. The venture is pursuing collaborative research agreements with leading scientists from top academic institutions. On March 26, 2018, IDT Corporation, or IDT, the former parent corporation of the Company, completed a tax-free spinoff (the "Spin-Off") of the Company's capital stock, through a pro rata distribution of common stock to its stockholders of record as of the close of business on March 13, 2018. The "Company" in these financial statements refers to Rafael Holdings on a consolidated basis from the date of the Spin-Off. All significant intercompany accounts and transactions have been eliminated in consolidation. All majority-owned subsidiaries are consolidated with all intercompany transactions and balances being eliminated in consolidation. The entities included in these financial statements are as follows: Company Country of Incorporation Percentage Rafael Holdings, Inc. United States – Delaware Broad Atlantic Associates, LLC United States – Delaware 100 % IDT 225 Old NB Road, LLC United States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % Rafael Realty Holdings, Inc. United States – Delaware 100 % Barer Institute, Inc. United States – Delaware 100 % Pharma Holdings, LLC United States – Delaware 90 % CS Pharma Holdings, LLC United States – Delaware 45 %* LipoMedix Pharmaceuticals Ltd. Israel 57.9 % * 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ending July 31, 2020). Operating results for the three and six months ended January 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at July 31, 2019 has been derived from the Company's audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended July 31, 2019, or the 2019 Form 10-K, as filed with the U.S. Securities and Exchange Commission ("SEC"). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) The Company disaggregates its revenue by source within its consolidated statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations which is also consistent with the guidance under ASC 842 , Leases Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due. Research and Development Costs and Expenses Research and development costs and expenses consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, Recently Adopted Accounting Pronouncements The FASB issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) in February 2016. The new standard, as amended by subsequent accounting updates thereto, replaces historical lease accounting guidance and requires lessees to account for a lease by recognizing right-of-use (ROU) asset and corresponding lease liability on the balance sheet. Lessor accounting under Topic 842 is largely unchanged from historical U.S. GAAP and generally aligns with accounting for revenue from contracts with customers (Topic 606). The Company initially adopted the new lease accounting standard as of August 1, 2019 and elected the optional transition method to apply the new standard prospectively. The Company elected the package of transition practical expedients, and therefore did not reassess: (1) whether any expired or existing contracts are or contain leases; (2) lease classification for any expired or existing leases; and (3) initial direct costs for any existing leases. Further, as of January 31, 2020 the Company was not a lessee under any leasing arrangements. which had, and will have, the following impacts on the Company: Topic 842 changed certain requirements regarding the classification of leases that could result in the Company recognizing certain long-term leases entered into or modified after August 1, 2019 as sales-type leases, as opposed to operating leases. The Company did not have a cumulative-effect adjustment as of the adoption date. The Company elected the practical expedient to not separate certain non-lease components from the lease component to which they relate because the timing and pattern of transfer for the lease components and non-lease components are the same and the related lease component is classified as an operating lease. As a result, the Company continues to present all rentals and reimbursements from tenants as a single line item Rental Income within the Consolidated Statement of Income. No reclassifications to prior periods for comparability were required.

Investment in Rafael Pharmaceut

Investment in Rafael Pharmaceuticals	6 Months Ended
	Jan. 31, 2020
Schedule of Investments [Abstract]
INVESTMENT IN RAFAEL PHARMACEUTICALS	NOTE 3 – INVESTMENT IN RAFAEL PHARMACEUTICALS Rafael Pharmaceuticals is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The Company owns equity interests and rights in Rafael Pharmaceuticals through a 90%-owned non-operating subsidiary, Pharma Holdings, LLC, or Pharma Holdings. Pharma Holdings owns 50% of CS Pharma Holdings, LLC ("CS Pharma"), a non-operating entity that owns equity interests in Rafael Pharmaceuticals. Accordingly, the Company holds an effective 45% indirect interest in the assets held by CS Pharma. Howard Jonas, Chairman of the Board and Chief Executive Officer of the Company, and Chairman of the Board of Rafael Pharmaceuticals owns 10% of Pharma Holdings. Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the collective ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the "Warrant"). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share, subject to certain adjustments, and will expire upon the earlier of December 31, 2020, a qualified initial public offering, or liquidation event of Rafael Pharmaceuticals. Pharma Holdings also holds certain governance rights in Rafael Pharmaceuticals including appointment of directors. CS Pharma holds 16.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock. CS Pharma owned a $10 million Series D Convertible Note, with 3.5% interest, in Rafael Pharmaceuticals which was converted in January 2019. The Company and its subsidiaries collectively own securities representing 51% of the outstanding capital stock of Rafael Pharmaceuticals and 38% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant). The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class. The Company serves as the managing member of Pharma Holdings, and Pharma Holdings serves as the managing member of CS Pharma, with broad authority to make all key decisions regarding their respective holdings. Any distributions that are made to CS Pharma from Rafael Pharmaceuticals that are in turn distributed by CS Pharma, will need to be made pro rata to all members, which would entitle Pharma Holdings to 50% (based on current ownership) of such distributions. Similarly, if Pharma Holdings were to distribute proceeds it receives from CS Pharma, it would do so on a pro rata basis, entitling the Company to 90% (based on current ownership) of such distributions. The Company evaluated its investments in Rafael Pharmaceuticals in accordance with ASC 323 , Investments - Equity Method and Joint Ventures Rafael Pharmaceuticals is a variable interest entity; however, the Company has determined that it is not the primary beneficiary as it does not have the power to direct the activities of Rafael Pharmaceuticals that most significantly impact Rafael Pharmaceuticals' economic performance. In addition, the interests held in Rafael Pharmaceuticals are Series D Convertible Preferred Stock and do not represent in-substance common stock. Howard Jonas has additional contractual rights to receive additional Rafael Pharmaceutical shares ("Bonus Shares") for an additional 10% of the fully diluted capital stock of Rafael Pharmaceuticals upon the achievement of certain milestones. The additional 10% is based on the fully diluted capital stock of Rafael Pharmaceuticals, excluding the remainder for the Warrant, at the time of issuance. If any of the milestones are met, the Bonus Shares are to be issued without any additional payment. Howard Jonas has the right to transfer the Bonus Shares, in his discretion, to others, including those who are instrumental to the future success of Rafael Pharmaceuticals.

Investment in LipoMedix

Investment in LipoMedix	6 Months Ended
	Jan. 31, 2020
Business Combinations [Abstract]
INVESTMENT IN LIPOMEDIX	NOTE 4 — INVESTMENT IN LIPOMEDIX LipoMedix is a development-stage, privately held Israeli company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The Company holds 57.9% of the issued and outstanding ordinary shares of LipoMedix and has consolidated this investment from the second quarter of fiscal 2018. In July 2018, the Company provided no-interest bridge financing of $875,000 to LipoMedix (the "2018 Bridge Note"), which was converted into 1,650,943 shares of LipoMedix on January 20, 2020 in accordance with its terms, thereby increasing the Company's ownership from 52.1% to 57.9%. In April 2019, the Company provided no-interest bridge financing of $250,000 to LipoMedix (the "2019 Bridge Note"). The 2019 Bridge Note converted into 471,698 shares of LipoMedix on September 28, 2019 which increased the Company's ownership on that date from 50.6% to 52.1%. In November 2019, the Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets. In January 2020, the Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020. Under the terms of the note, as long as it remains outstanding, LipoMedix may not incur any additional debt, make any shareholder distributions, or assume any liens on property or assets.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5 — FAIR VALUE MEASUREMENTS The Fair Value Measurements and Disclosures topic of the FASB ASC requires disclosures about how fair value is determined for assets and liabilities and a hierarchy for which these assets and liabilities must be grouped is established, based on significant levels of inputs as follows: Level 1 – Level 2 – Level 3 – The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following is a listing of the Company's assets required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of January 31, 2020 and July 31, 2019: January 31, 2020 Level 1 Level 2 Level 3 Total Available-for-sale securities: (unaudited, in thousands) Hedge Funds $ — $ — $ 5,645 $ 5,645 Total $ — $ — $ 5,645 $ 5,645 July 31, 2019 Level 1 Level 2 Level 3 Total Available-for-sale securities: (unaudited, in thousands) Hedge Funds $ — $ — $ 5,125 $ 5,125 Total $ — $ — $ 5,125 $ 5,125 At January 31, 2020 and July 31, 2019, the Company did not have any liabilities measured at fair value on a recurring basis. The following table summarizes the change in the balance of the Company's assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3). Six Months Ended 2020 2019 (unaudited, in thousands) Balance, beginning of period $ 5,125 $ 12,118 Conversion of Series D Convertible Note — (7,900 ) Total gain included in earnings 520 (52 ) Balance, end of period $ 5,645 $ 4,166 At July 31, 2018, the fair value of the Rafael Pharmaceuticals convertible promissory notes, which were classified as Level 3, was estimated based on a valuation of Rafael Pharmaceuticals by reference to recent transactions in its securities, the September 2016 Series D Convertible Note investment, as well as utilizing a discounted cash flow technique under the Income Approach and other factors that could not be corroborated by the market. The Note was converted into shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals in January 2019. Prior to the Spin-Off, IDT contributed a $2.0 million investment in securities of another entity that are not liquid, which were included in Investments – Other Pharmaceuticals in the accompanying consolidated balance sheets. The investment is accounted for using the cost method; therefore, this investment is not measured at fair value. Fair Value of Other Financial Instruments The estimated fair value of the Company's other financial instruments was determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting these data to develop estimates of fair value. Consequently, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. Cash and cash equivalents, prepaid expenses and other current assets, and other current liabilities. Other assets and other liabilities. The Company's financial instruments include trade accounts receivable, trade accounts payable, and due from related parties. The recorded carrying amount of trade accounts receivable, trade accounts payable and due from related parties approximate their fair value due to their short-term nature. Other than noted above, the Company did not have any other assets or liabilities that were measured at fair value on a recurring basis as of January 31, 2020 or July 31, 2019.

Trade Accounts Receivable

Trade Accounts Receivable	6 Months Ended
	Jan. 31, 2020
Receivables [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 6 — TRADE ACCOUNTS RECEIVABLE Trade Accounts Receivable consisted of the following: January 31, July 31, (unaudited, in thousands) Trade Accounts Receivable – Third Party $ 449 $ 561 Trade Accounts Receivable – Related Party 46 11 Less: Allowance for Doubtful Accounts (170) (122) Trade Accounts Receivable, net $ 325 $ 450 The current portion of deferred rental income included in Prepaid Expenses and Other Current Assets was approximately $23,000 and $34,000 as of January 31, 2020 and July 31, 2019, respectively. The noncurrent portion of deferred rental income included in Other Assets was approximately $1.4 million as of January 31, 2020 and July 31, 2019.

Property and Equipment

Property and Equipment	6 Months Ended
	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 7 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following: January 31, July 31, (unaudited, in thousands) Building and Improvements $ 54,676 $ 54,241 Land 10,412 10,412 Furniture and Fixtures 1,145 1,145 Other 276 255 66,509 66,053 Less: Accumulated Depreciation and Amortization (18,259 ) (17,320 ) Total $ 48,250 $ 48,733 Other property and equipment consists of furniture and fixtures, office and other equipment and miscellaneous computer hardware. Depreciation and amortization expense pertaining to property and equipment was approximately $473,000 and $431,000 for the three months ended January 31, 2020 and 2019, respectively, and $939,000 and $860,000 for the six months ended January 31, 2020 and 2019, respectively. The Company's headquarters are located at 520 Broad Street in Newark where it occupies office space in the building owned by its subsidiary.

Loss Per Share

Loss Per Share	6 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
LOSS PER SHARE	NOTE 8 — LOSS PER SHARE Basic net loss per share is computed by dividing net loss attributable to all classes of common stockholders of the Company by the weighted average number of shares of all classes of common stock outstanding during the applicable period. Diluted loss per share includes potentially dilutive securities such as stock options and other convertible instruments. The following table summarizes the Company's potentially dilutive securities which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: January 31, July 31, (unaudited) Stock Options 586,874 587,133 Convertible Note — 1,847,594 Total 586,874 2,434,727 In the three and six months ended January 31, 2020 and 2019, the diluted loss per share computation equals basic loss per share because the Company had a net loss and the impact of the assumed exercise of stock options and conversion of the convertible note would have been anti-dilutive.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jan. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 — RELATED PARTY TRANSACTIONS The Company has historically maintained an intercompany balance due to/from related parties that relates to cash advances for investments, loan repayments, charges for services provided to the Company by IDT and payroll costs for the Company's personnel that were paid by IDT. This is partially offset by rental income paid to the Company by various companies under common control to IDT. The Company recorded expense of approximately $142,000 in related party services to IDT, of which approximately $29,000 is included in due to related parties at January 31, 2020. The Company provides Rafael Pharmaceuticals with administrative, finance, accounting, tax and legal services. Howard S. Jonas serves as a Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. The Company billed Rafael Pharmaceuticals $120,000 during each of the first and second quarters of fiscal 2020. As of January 31, 2020, Rafael Pharmaceuticals owed the Company $120,000 included in "Due from Rafael Pharmaceuticals". On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. At issuance, the Company recorded a debt discount of approximately $70,000 related to the beneficial conversion feature of the note and amortized approximately $16,000 of the discount in fiscal 2019 which was recorded as interest expense. In addition, the Company recorded approximately $650,000 of interest expense for the year ended July 31, 2019. In August 2019, the note including accrued interest of approximately $667,000 was converted into 1,849,749 shares of common stock. On January 10, 2019, Pharma Holdings partially exercised a warrant to purchase 5.1 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $6.4 million, of which $640,000 was contributed by Howard Jonas. On January 23, 2019, Pharma Holdings partially exercised a warrant to purchase 36.3 million shares of Series D Convertible Preferred Stock of Rafael Pharmaceuticals for $34.4 million, of which $3.4 million was contributed by Howard Jonas. On January 29, 2020, in connection with the vesting of certain restricted shares of Class B common stock held by an officer of the Company, the Company withheld 5,238 shares to pay for the payroll taxes on the officer's behalf, totalling approximately $116,000. The Company leases space to related parties which represented approximately 43% and 51% of the Company's total revenue for the three months ended January 31, 2020 and 2019, respectively, and 43% and 48% for the six months ended January 31, 2020 and 2019, respectively. See Note 14 for future minimum rent payments from related parties and other tenants.

Income Taxes

Income Taxes	6 Months Ended
	Jan. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 — INCOME TAXES On December 22, 2017, the U.S. government enacted "An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018", which is commonly referred to as "The Tax Cuts and Jobs Act" (the "Tax Act"). The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred ("transition tax"), and creates new taxes on certain foreign sourced earnings. At July 31, 2019, the Company did not have any undistributed earnings of its foreign subsidiaries. As a result, no additional income or withholding taxes were provided for, for the undistributed earnings or any additional outside basis differences inherent in the foreign entities. The Company reviewed the global intangible low taxed income ("GILTI") and base erosion anti-abuse tax ("BEAT) that became effective August 1, 2018 and has not recorded any impact associated with either. At July 31, 2019, the Company had federal net operating loss ("NOL") carryforwards from domestic operations of approximately $22.3 million to offset future taxable income. The Company has state NOLs of $3.2 million. The Company has NOL carryforwards from foreign operations of $1.2 million. As part of the Tax Act, federal NOLs generated in 2018 and later are not subject to an expiration period and are available to offset 80% of taxable income in the year in which they are utilized. The federal NOL carryforwards generated prior to 2018 will begin to expire in 2026. The state NOLs will begin to expire in 2038 and foreign NOLs do not expire. The Company anticipates that its assumptions and estimates may change as a result of future guidance and interpretation from the Internal Revenue Service, the FASB, and various other taxing jurisdictions. In particular, the Company anticipates that the U.S. state jurisdictions will continue to determine and announce their conformity with or decoupling from the Tax Act, either in its entirety or with respect to specific provisions. Legislative and interpretive actions could result in adjustments to the Company's provisional estimates when the accounting for the income tax effects of the Tax Act is completed.

Business Segment Information

Business Segment Information	6 Months Ended
	Jan. 31, 2020
Segment Reporting [Abstract]
BUSINESS SEGMENT INFORMATION	NOTE 11 — BUSINESS SEGMENT INFORMATION The Company conducts business as two operating segments, Real Estate and Pharmaceuticals. The Company's reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company's President. The Real Estate segment consists of the Company's real estate holdings, including a building at 520 Broad Street in Newark, New Jersey that houses headquarters for the Company and certain affiliates and its associated public garage, an office/data center building in Piscataway, New Jersey and a portion of an office building in Israel. The Pharmaceuticals segment is comprised of preferred equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix and Barer. To date, the Pharmaceuticals segment has not generated any revenues. The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Pharmaceuticals segment based primarily on research and development efforts and results of clinical trials and the Real Estate segment based primarily on results of operations. All investments in Rafael Pharmaceuticals and assets and expenses associated with LipoMedix and Barer are tracked separately in the Pharmaceuticals segment. All corporate costs are allocated to the Real Estate segment. Operating results for the business segments of the Company are as follows: (unaudited, in thousands) Real Estate Pharmaceuticals Total Three Months Ended January 31, 2020 Revenues $ 1,236 $ — $ 1,236 Loss from operations (1,392 ) (514 ) (1,906 ) Three Months Ended January 31, 2019 Revenues $ 1,017 $ — $ 1,017 Loss from operations (1,109 ) (297 ) (1,406 ) (unaudited, in thousands) Real Estate Pharmaceuticals Total Six Months Ended January 31, 2020 Revenues $ 2,446 $ — $ 2,446 Loss from operations (2,668 ) (780 ) (3,448 ) Six Months Ended January 31, 2019 Revenues $ 2,152 $ — $ 2,152 Loss from operations (1,823 ) (703 ) (2,526 ) Geographic Information Revenues from tenants located outside of the United States were generated entirely from tenants located in Israel. Revenues from these non-United States customers as a percentage of total revenues were as follows (revenues by country are determined based on the location of the related facility): Three Months Ended January 31, (unaudited) 2020 2019 Revenue from tenants located in Israel 6 % 2 % Six Months Ended January 31, (unaudited) 2020 2019 Revenue from tenants located in Israel 6% 2 % Net long-lived assets and total assets held outside of the United States, which are located in Israel, were as follows: (unaudited, in thousands) United States Israel Total January 31, 2020 Long-lived assets, net $ 46,623 $ 1,627 $ 48,250 Total assets 135,699 3,537 139,236 July 31, 2019 Long-lived assets, net $ 47,096 $ 1,637 $ 48,733 Total assets 138,535 3,608 142,143

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 — COMMITMENTS AND CONTINGENCIES Legal Proceedings Under a Founders Agreement among LipoMedix and other parties, two of LipoMedix founders would become entitled to consulting payments in the approximate amounts of $385,000 and $358,000, respectively, upon the satisfaction of certain conditions thereto. LipoMedix believes that those conditions have not been satisfied and does not believe that they are likely to be satisfied until LipoMedix is successful in raising significant capital in the future. On September 17, 2018, LipoMedix was notified of a claim initiated by one of its founders seeking payment of consulting fees in the amount of approximately $377,000 and seeking to place restrictions on LipoMedix's bank accounts and other assets to protect his claim. LipoMedix did not believe that the individual had the right to receive any payment at the current time. LipoMedix responded to the demand for the placement of restrictions on its assets. On November 26, 2018, the court denied the request by the founder to place restrictions on the assets. In May 2019, LipoMedix received a letter from the other founder requesting payment of his consulting fees. On July 15, 2019, the parties settled the matters and the two founders will be paid a percentage of future investments and certain other proceeds. On July 12, 2019, the Company received a Citation and Notification of Penalty from the Occupational Safety and Health Administration of the U.S. Department of Labor or OSHA, related to an OSHA inspection of 520 Broad Street, Newark, New Jersey. The citation seeks to impose penalties related to alleged violations of the Occupation Safety and Health Act of 1970 at 520 Broad Street. On July 31, 2019, the Company filed a Notice of Contest with OSHA contesting the citation in its entirety. On February 14, 2020 the Company entered into a Settlement Agreement with OSHA, as related to the citation received on July 12, 2019. As part of the Settlement Agreement, the Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021. The Company accounts for contingencies when a loss is considered probable and can be reasonably estimated. For the matters disclosed above a legal accrual for approximately $225,000 has been recorded for legal fees and losses believed to be both probable and reasonably estimable, but an exposure to additional loss may exist in excess of the amount accrued. On December 31, 2019, an employee of the Company filed a complaint in connection with the incident that led to the OSHA inspection noted above for personal injuries against the Company and other parties in the New Jersey Supreme Court for an incident that took place on January 31, 2019 at 520 Broad Street. The Company intends to vigorously defend this matter. The loss is considered remote and no accrual has been recorded. The Company may from time to time be subject to legal proceedings that may arise in the ordinary course of business. Although there can be no assurance in this regard, the Company does not expect any of those legal proceedings to have a material adverse effect on the Company's results of operations, cash flows or financial condition.

Equity

Equity	6 Months Ended
	Jan. 31, 2020
Equity [Abstract]
EQUITY	NOTE 13 — EQUITY On November 15, 2018, Howard Jonas entered into an agreement to purchase a convertible note from the Company for $15.0 million that was convertible into shares of Class B common stock at $8.47 per share. The term of the note was three years with interest on the principal amount at a rate of 6% per annum, compounded quarterly. In August 2019, the note including interest of approximately $667,000 was converted into 1,849,749 shares of Class B common stock. Pursuant to the Company's 2018 Equity Incentive Plan, each of our three non-employee directors of the Company was granted 4,203 restricted shares of our Class B common stock in January 2020 which fully vested on the date of the grant. The fair value of the awards on the date of the grant was approximately $208,000 which was included in selling, general and administrative expense. Stock Options A summary of stock option activity for the Company is as follows: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2019 587,133 $ 4.90 3.66 $ 2,877 Granted — — — — Exercised — — — — Cancelled / Forfeited (259 ) 4.90 — — Outstanding at January 31, 2020 586,874 $ 4.90 3.15 $ 2,876 Exercisable at January 31, 2020 586,874 $ 4.90 3.15 $ 2,876 During the six months ended January 31, 2020, 259 options were canceled due to employee terminations. At January 31, 2020, there was no unrecognized compensation cost related to non-vested stock options. Restricted Stock The fair value of restricted shares of the Company's Class B common stock is determined based on the closing price of the Company's Class B common stock on the grant date. Share awards generally vest on a graded basis over three years of service. A summary of the status of the Company's grants of restricted shares of Class B common stock is presented below: (unaudited) Number of Weighted- Fair Value Outstanding at July 31, 2019 156,426 $ 10.41 Granted 20,863 20.49 Vested (14,144 ) 17.25 Cancelled / Forfeited — — NON-VESTED SHARES AT January 31, 2020 163,145 $ 11.91 At January 31, 2020, there was $1.5 million of total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which is expected to be recognized over the next 2.40 years.

Leases

Leases	6 Months Ended
	Jan. 31, 2020
Leases [Abstract]
LEASES	NOTE 14 — LEASES The Company is the lessor of certain properties which are leased to tenants under net operating leases with initial term expiration dates ranging from 2021 to 2028. Lease income included on the Consolidated Statements of Operations for the three and six months ended January 31, 2020, was $1.2 million and $2.4 million, respectively. The future contractual minimum lease payments to be received (excluding operating expense reimbursements) by the Company as of January 31, 2020, under non-cancelable operating leases which expire on various dates through 2028 are as follows: Year ending July 31, Related Parties Other Total (unaudited, in thousands) 2020 $ 1,006 $ 598 $ 1,604 2021 2,041 1,115 3,156 2022 2,078 968 3,046 2023 2,117 640 2,757 2024 2,155 538 2,693 Thereafter 1,659 2,494 4,153 Total Minimum Future Rental Income $ 11,056 $ 6,353 $ 17,409 The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel. The annual rent is approximately $2.0 million in the aggregate. The related parties have the right to terminate the domestic leases upon four months' notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months' notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.

Subsequent Events

Subsequent Events	6 Months Ended
	Jan. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 — SUBSEQUENT EVENTS On February 3, 2020, Rafael Pharmaceuticals entered into a Line of Credit Loan Agreement ("Line of Credit Agreement") with RP Finance, LLC ("RP Finance"), which provides a revolving commitment of up to $50,000,000 to fund clinical trials and other capital needs. The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. Howard Jonas, the Company's Chairman and Chief Executive Officer, is Chairman of the Board of Rafael Pharmaceuticals and owns an equity interest in Rafael Pharmaceuticals. Mr. Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance is owned by other shareholders of Rafael Pharmaceuticals. Under the Line of Credit Agreement, all funds borrowed will bear interest at the mid-term Applicable Federal Rate published by the U.S. Internal Revenue Service. The maturity date is the earlier of February 3, 2025, upon a change of control of Rafael Pharmaceuticals or a sale of Rafael Pharmaceuticals or its assets. Rafael Pharmaceuticals can draw on the facility on 60 days' notice. The funds borrowed under the Line of Credit Agreement must be repaid out of certain proceeds from equity sales by Rafael Pharmaceuticals. In connection with entering into the Line of Credit Agreement, Rafael Pharmaceuticals agreed to issue to RP Finance shares of its common stock representing 12% of the issued and outstanding shares of Rafael Pharmaceuticals common stock, with such interest subject to anti-dilution protection as set forth in the Line of Credit Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company's fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated (e.g., fiscal 2020 refers to the fiscal year ending July 31, 2020). Operating results for the three and six months ended January 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2020. The balance sheet at July 31, 2019 has been derived from the Company's audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended July 31, 2019, or the 2019 Form 10-K, as filed with the U.S. Securities and Exchange Commission ("SEC").
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606) The Company disaggregates its revenue by source within its consolidated statements of operations. As an owner and operator of real estate, the Company derives the majority of its revenue from leasing office and parking space to tenants at its properties. In addition, the Company earns revenue from recoveries from tenants, consisting of amounts due from tenants for common area maintenance, real estate taxes and other recoverable costs. Revenue from recoveries from tenants is recorded together with rental income on the consolidated statements of operations which is also consistent with the guidance under ASC 842 , Leases Contractual rental revenue is reported on a straight-line basis over the terms of the respective leases. Accrued rental income, included within Other Assets on the consolidated balance sheets, represents cumulative rental income earned in excess of rent payments received pursuant to the terms of the individual lease agreements. The Company also earns revenue from parking which is derived primarily from monthly and transient daily parking. The monthly and transient daily parking revenue falls within the scope of ASC 606 and is accounted for at the point in time when control of the goods or services transfers to the customer and the Company's performance obligation is satisfied, consistent with the Company's previous accounting. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent payments or parking customers to pay amounts due.
Research and Development Costs and Expenses	Research and Development Costs and Expenses Research and development costs and expenses consist primarily of salaries and related personnel expenses, stock-based compensation, fees paid to external service providers, laboratory supplies, costs for facilities and equipment, license costs, and other costs for research and development activities. Research and development expenses are recorded in operating expenses in the period in which they are incurred. Estimates have been used in determining the liability for certain costs where services have been performed but not yet invoiced. The Company monitors levels of performance under each significant contract for external service providers, including the extent of patient enrollment and other activities through communications with the service providers to reflect the actual amount expended. Contingent milestone payments associated with acquiring rights to intellectual property are recognized when probable and estimable. These amounts are expensed to research and development when there is no alternative future use associated with the intellectual property.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The FASB issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) in February 2016. The new standard, as amended by subsequent accounting updates thereto, replaces historical lease accounting guidance and requires lessees to account for a lease by recognizing right-of-use (ROU) asset and corresponding lease liability on the balance sheet. Lessor accounting under Topic 842 is largely unchanged from historical U.S. GAAP and generally aligns with accounting for revenue from contracts with customers (Topic 606). The Company initially adopted the new lease accounting standard as of August 1, 2019 and elected the optional transition method to apply the new standard prospectively. The Company elected the package of transition practical expedients, and therefore did not reassess: (1) whether any expired or existing contracts are or contain leases; (2) lease classification for any expired or existing leases; and (3) initial direct costs for any existing leases. Further, as of January 31, 2020 the Company was not a lessee under any leasing arrangements. which had, and will have, the following impacts on the Company: Topic 842 changed certain requirements regarding the classification of leases that could result in the Company recognizing certain long-term leases entered into or modified after August 1, 2019 as sales-type leases, as opposed to operating leases. The Company did not have a cumulative-effect adjustment as of the adoption date. The Company elected the practical expedient to not separate certain non-lease components from the lease component to which they relate because the timing and pattern of transfer for the lease components and non-lease components are the same and the related lease component is classified as an operating lease. As a result, the Company continues to present all rentals and reimbursements from tenants as a single line item Rental Income within the Consolidated Statement of Income. No reclassifications to prior periods for comparability were required.

Description of Business (Tables

Description of Business (Tables)	6 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of entities majority-owned subsidiaries	Company Country of Incorporation Percentage Rafael Holdings, Inc. United States – Delaware Broad Atlantic Associates, LLC United States – Delaware 100 % IDT 225 Old NB Road, LLC United States – Delaware 100 % IDT R.E. Holdings Ltd. Israel 100 % Rafael Realty Holdings, Inc. United States – Delaware 100 % Barer Institute, Inc. United States – Delaware 100 % Pharma Holdings, LLC United States – Delaware 90 % CS Pharma Holdings, LLC United States – Delaware 45 %* LipoMedix Pharmaceuticals Ltd. Israel 57.9 % * 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of balance of assets measured at fair value on a recurring basis	January 31, 2020 Level 1 Level 2 Level 3 Total Available-for-sale securities: (unaudited, in thousands) Hedge Funds $ — $ — $ 5,645 $ 5,645 Total $ — $ — $ 5,645 $ 5,645 July 31, 2019 Level 1 Level 2 Level 3 Total Available-for-sale securities: (unaudited, in thousands) Hedge Funds $ — $ — $ 5,125 $ 5,125 Total $ — $ — $ 5,125 $ 5,125
Schedule of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3)	Six Months Ended 2020 2019 (unaudited, in thousands) Balance, beginning of period $ 5,125 $ 12,118 Conversion of Series D Convertible Note — (7,900 ) Total gain included in earnings 520 (52 ) Balance, end of period $ 5,645 $ 4,166

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	6 Months Ended
	Jan. 31, 2020
Receivables [Abstract]
Schedule of trade accounts receivable	January 31, July 31, (unaudited, in thousands) Trade Accounts Receivable – Third Party $ 449 $ 561 Trade Accounts Receivable – Related Party 46 11 Less: Allowance for Doubtful Accounts (170) (122) Trade Accounts Receivable, net $ 325 $ 450

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	January 31, July 31, (unaudited, in thousands) Building and Improvements $ 54,676 $ 54,241 Land 10,412 10,412 Furniture and Fixtures 1,145 1,145 Other 276 255 66,509 66,053 Less: Accumulated Depreciation and Amortization (18,259 ) (17,320 ) Total $ 48,250 $ 48,733

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Schedule of common share equivalents, basic and dilutive loss per share	January 31, July 31, (unaudited) Stock Options 586,874 587,133 Convertible Note — 1,847,594 Total 586,874 2,434,727

Business Segment Information (T

Business Segment Information (Tables)	6 Months Ended
	Jan. 31, 2020
Segment Reporting [Abstract]
Schedule of operating results for the business segments	(unaudited, in thousands) Real Estate Pharmaceuticals Total Three Months Ended January 31, 2020 Revenues $ 1,236 $ — $ 1,236 Loss from operations (1,392 ) (514 ) (1,906 ) Three Months Ended January 31, 2019 Revenues $ 1,017 $ — $ 1,017 Loss from operations (1,109 ) (297 ) (1,406 ) (unaudited, in thousands) Real Estate Pharmaceuticals Total Six Months Ended January 31, 2020 Revenues $ 2,446 $ — $ 2,446 Loss from operations (2,668 ) (780 ) (3,448 ) Six Months Ended January 31, 2019 Revenues $ 2,152 $ — $ 2,152 Loss from operations (1,823 ) (703 ) (2,526 )
Schedule of revenue from tenants by geographic areas	Three Months Ended January 31, (unaudited) 2020 2019 Revenue from tenants located in Israel 6 % 2 % Six Months Ended January 31, (unaudited) 2020 2019 Revenue from tenants located in Israel 6% 2 %
Schedule of net long-lived assets and total assets by geographic areas	(unaudited, in thousands) United States Israel Total January 31, 2020 Long-lived assets, net $ 46,623 $ 1,627 $ 48,250 Total assets 135,699 3,537 139,236 July 31, 2019 Long-lived assets, net $ 47,096 $ 1,637 $ 48,733 Total assets 138,535 3,608 142,143

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2019 587,133 $ 4.90 3.66 $ 2,877 Granted — — — — Exercised — — — — Cancelled / Forfeited (259 ) 4.90 — — Outstanding at January 31, 2020 586,874 $ 4.90 3.15 $ 2,876 Exercisable at January 31, 2020 586,874 $ 4.90 3.15 $ 2,876
Schedule of grants of restricted shares of Class B common stock	(unaudited) Number of Weighted- Fair Value Outstanding at July 31, 2019 156,426 $ 10.41 Granted 20,863 20.49 Vested (14,144 ) 17.25 Cancelled / Forfeited — — NON-VESTED SHARES AT January 31, 2020 163,145 $ 11.91

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jan. 31, 2020
Leases [Abstract]
Schedule of non-cancelable operating leases	Year ending July 31, Related Parties Other Total (unaudited, in thousands) 2020 $ 1,006 $ 598 $ 1,604 2021 2,041 1,115 3,156 2022 2,078 968 3,046 2023 2,117 640 2,757 2024 2,155 538 2,693 Thereafter 1,659 2,494 4,153 Total Minimum Future Rental Income $ 11,056 $ 6,353 $ 17,409

Description of Business (Detail

Description of Business (Details)	6 Months Ended
	Jan. 31, 2020
Rafael Holdings, Inc. [Member]
Country of Incorporation	United States – Delaware
Broad Atlantic Associates, LLC [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
IDT 225 Old NB Road, LLC [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
IDT R.E. Holdings Ltd. [Member]
Country of Incorporation	Israel
Percentage Owned	100.00%
Rafael Realty Holdings, Inc. [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Barer Institute, Inc. [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	100.00%
Pharma Holdings, LLC [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	90.00%
CS Pharma Holdings, LLC [Member]
Country of Incorporation	United States – Delaware
Percentage Owned	45.00%	[1]
Lipomedix Pharmaceuticals Ltd. [Member]
Country of Incorporation	Israel
Percentage Owned	57.90%
[1]	50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC.

Description of Business (Deta_2

Description of Business (Details Textual)	6 Months Ended
	Jan. 31, 2020
CS Pharma Holdings, LLC [Member]
Description of Business (Textual)
Percentage owned	50.00%
Interest percentage	45.00%
IDT-Rafael Holdings, LLC [Member]
Description of Business (Textual)
Percentage owned	90.00%

Investment in Rafael Pharmace_2

Investment in Rafael Pharmaceuticals (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2020
Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Ownership percentage in non-operating subsidiary		50.00%
Howard Jonas [Member] | CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Indirect interest in assets held, percentage		45.00%
Ownership interest, percentage		10.00%
IDT-Rafael Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Fully diluted		51.00%
Bonus shares		38.00%
IDT-Rafael Holdings, LLC [Member] | Series D Convertible Preferred Stock [Member]
Investment in Rafael Pharmaceuticals (Textual)
Warrants expiry date		Dec. 31, 2020
Exercise price of warrants or rights, description		Pharma Holdings holds 36.7 million shares of Rafael Pharmaceuticals Series D Convertible Preferred Stock and a warrant to increase the collective ownership of Pharma Holdings and CS Pharma to up to 56% of the fully diluted equity interests in Rafael Pharmaceuticals (the “Warrant”). The Warrant is exercisable at the lower of 70% of the price sold in an equity financing, or $1.25 per share.
Purchase of exercise the warrant, shares		16,700,000
Exercise of warrants purchases, description		The Series D Convertible Preferred Stock has a stated value of $1.25 per share (subject to appropriate adjustment to reflect any stock split, combination, reclassification or reorganization of the Series D Preferred Stock or any dilutive issuances, as described below). Holders of Series D Stock are entitled to receive non-cumulative dividends when, as and if declared by the board of Rafael Pharmaceuticals, prior to any dividends to any other class of capital stock of Rafael Pharmaceuticals. In the event of any liquidation, dissolution or winding up of the Company, or in the event of any deemed liquidation, proceeds from such liquidation, dissolution, winding up shall be distributed first to the holders of Series D Stock. Except with respect to certain major decisions, or as required by law, holders of Series D Stock vote together with the holders of the other preferred stock and common stock and not as a separate class.
CS Pharma Holdings, LLC [Member]
Investment in Rafael Pharmaceuticals (Textual)
Ownership percentage in non-operating subsidiary		90.00%
Indirect interest in assets held, percentage		45.00%
Ownership interest, percentage		50.00%
CS Pharma Holdings, LLC [Member] | Series D Convertible [Member]
Investment in Rafael Pharmaceuticals (Textual)
Convertible promissory note, rate of interest	3.50%
Principal amount	$ 10,000

Investment in LipoMedix (Detail

Investment in LipoMedix (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	Jan. 30, 2020	Nov. 30, 2019	Apr. 30, 2019	Mar. 31, 2018	Jan. 31, 2020
LipoMedix [Member]
Investment in LipoMedix (Textual)
No-interest bridge financing					$ 875,000
LipoMedix [Member] | Minimum [Member]
Investment in LipoMedix (Textual)
Ownership Percentage					52.10%
LipoMedix [Member] | Maximum [Member]
Investment in LipoMedix (Textual)
Ownership Percentage					57.90%
LipoMedix [Member]
Investment in LipoMedix (Textual)
Issued and outstanding ordinary shares, percentage				57.90%
Description of acquisition entity	The Company provided bridge financing in the principal amount of $125,000 to LipoMedix with a maturity date of May 3, 2020.	The Company provided bridge financing in the principal amount of $100,000 to LipoMedix with a maturity date of May 3, 2020.	The Company provided no-interest bridge financing of $250,000 to LipoMedix (the "2019 Bridge Note"). The 2019 Bridge Note converted into 471,698 shares of LipoMedix on September 28, 2019 which increased the Company's ownership on that date from 50.6% to 52.1%.
Bridge Note Converted					1,650,943

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Available-for-sale securities:
Hedge Funds	$ 5,645	$ 5,125
Total	5,645	5,125
Level 1 [Member]
Available-for-sale securities:
Hedge Funds
Total
Level 2 [Member]
Available-for-sale securities:
Hedge Funds
Total
Level 3 [Member]
Available-for-sale securities:
Hedge Funds	5,645	5,125
Total	$ 5,645	$ 5,125

Fair Value Measurements (Deta_2

Fair Value Measurements (Details 1) - Level 3 [Member] - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Balance, beginning of period	$ 5,125	$ 12,118
Conversion of Series D Convertible Note		(7,900)
Total (loss) gains included in earnings	520	(52)
Balance, end of period	$ 5,645	$ 4,166

Fair Value Measurements (Deta_3

Fair Value Measurements (Details Textual) $ in Thousands	Jan. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Spin-Off, IDT contribution investment amount	$ 2,000

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Receivables [Abstract]
Trade Accounts Receivable - Third Party	$ 449	$ 561
Trade Accounts Receivable - Related Party	46	11
Less: Allowance for Doubtful Accounts	(170)	(122)
Trade Accounts Receivable, net	$ 325	$ 450

Trade Accounts Receivable (De_2

Trade Accounts Receivable (Details Textual) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Trade Accounts Receivable (Textual)
Prepaid expenses and other current assets	$ 326	$ 507
Other assets	1,450	1,412
Noncurrent Portion of Deferred Rental Income [Member]
Trade Accounts Receivable (Textual)
Other assets	1,400	1,400
Current Portion of Deferred Rental Income [Member]
Trade Accounts Receivable (Textual)
Prepaid expenses and other current assets	$ 23	$ 34

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Property, Plant and Equipment [Abstract]
Building and Improvements	$ 54,676	$ 54,241
Land	10,412	10,412
Furniture and Fixtures	1,145	1,145
Other	276	255
Property and equipment, gross	66,509	66,053
Less: Accumulated Depreciation and Amortization	(18,259)	(17,320)
Total	$ 48,250	$ 48,733

Property and Equipment (Detai_2

Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Property and Equipment (Textual)
Depreciation and amortization expense pertaining to property and equipment	$ 473	$ 431	$ 939	$ 860

Loss Per Share (Details)

Loss Per Share (Details) - shares	6 Months Ended
	Jan. 31, 2020	Jul. 31, 2019
Total	586,874	2,434,727
Convertible Note [Member]
Total		1,847,594
Stock Options [Member]
Total	586,874	587,133

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 23, 2019	Jan. 10, 2019	Jan. 29, 2020	Aug. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019	Jul. 31, 2019	Oct. 31, 2019	Nov. 15, 2018
Related Party Transactions (Textual)
Debt discount							$ 54	$ 5
Percentage of total revenue					43.00%	51.00%	43.00%	48.00%
Class B common stock
Related Party Transactions (Textual)
Interest expense				$ 667,000
Conversion of common stock shares				1,849,749
Restricted shares vested							4,203
Howard S. Jonas [Member]
Related Party Transactions (Textual)
Due to related parties	$ 3,400	$ 640,000
Officer's [Member] | Class B common stock
Related Party Transactions (Textual)
Restricted shares vested			5,238
Payroll Taxes			$ 116,000
IDT Rafael Holdings, LLC [Member]
Related Party Transactions (Textual)
Warrant exercised	36,300,000	5,100,000
Proceeds from warrant exercises	$ 34,400	$ 6,400
At issuance [Member]
Related Party Transactions (Textual)
Debt discount									$ 16,000
Beneficial conversion feature									70,000
Interest expense									$ 650,000
Howard Jonas [Member]
Related Party Transactions (Textual)
Convertible debt											$ 15,000
Convertible conversion price per share											$ 8.47
Interest rate on principal amount											6.00%
IDT [Member]
Related Party Transactions (Textual)
Due to related parties					$ 142,000		$ 142,000
Due from related parties					29,000		29,000
Rafael Pharmaceuticals [Member]
Related Party Transactions (Textual)
Due from related parties					$ 120,000		$ 120,000			$ 120,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jan. 31, 2020	Jul. 31, 2019
Income Taxes (Textual)
Federal statutory corporate tax, description	The Tax Act provides for comprehensive tax legislation that, among other things, reduces the U.S. federal statutory corporate tax rate from 35.0% to 21.0% effective January 1, 2018, broadens the U.S. federal income tax base, requires companies to pay a one-time repatriation tax on earnings of certain foreign subsidiaries that were previously tax deferred ("transition tax"), and creates new taxes on certain foreign sourced earnings.
Federal net operating loss		$ 22,300
Federal net operating loss, expiration date	Jul. 31, 2038	Jul. 31, 2026
Percentage of available to offset of taxable income		80.00%
Federal net operating loss		$ 3,200
Net operating loss foreign operations		$ 1,200

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Segment Reporting Information [Line Items]
Revenues	$ 1,236	$ 1,017	$ 2,446	$ 2,152
Loss from operations	(1,906)	(1,406)	(3,448)	(2,526)
Real Estate [Member]
Segment Reporting Information [Line Items]
Revenues	1,236	1,017	2,446	2,152
Loss from operations	(1,392)	(1,109)	(2,668)	(1,823)
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Revenues
Loss from operations	$ (514)	$ 297	$ (780)	$ (703)

Business Segment Information _2

Business Segment Information (Details 1)	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2020	Jan. 31, 2019
Revenue Benchmark [Member]
Segment Reporting Information [Line Items]
Revenue from tenants located in Israel	6.00%	2.00%	6.00%	2.00%

Business Segment Information _3

Business Segment Information (Details 2) - USD ($) $ in Thousands	Jan. 31, 2020	Jul. 31, 2019
Segment Reporting Information [Line Items]
Long-lived assets, net	$ 48,250	$ 48,733
Total Assets	139,236	142,143
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	46,623	47,096
Total Assets	135,699	138,535
Israel [Member]
Segment Reporting Information [Line Items]
Long-lived assets, net	1,627	1,637
Total Assets	$ 3,537	$ 3,608

Business Segment Information _4

Business Segment Information (Details Textual)	6 Months Ended
	Jan. 31, 2020Segments
Business Segment Information (Textual)
Number of operating segments	2

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Jul. 12, 2019	Sep. 17, 2018	Jan. 31, 2020
Commitments and Contingencies (Textual)
Legal fees	$ 225
Settlement agreement, Description			The Company agreed to pay a penalty of $127,294 in eight quarterly installment payments through November 2021.
LipoMedix Pharmaceuticals Ltd. [Member]
Commitments and Contingencies (Textual)
Payment of consulting fees		$ 377
Consulting payments amounts			$ 358,000
Other parties [Member]
Commitments and Contingencies (Textual)
Consulting payments amounts			$ 385,000

Equity (Details)

Equity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2020USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding, Beginning balance | shares | shares	587,133
Number of Options, Granted | shares | shares
Number of Options, Exercised | shares
Number of Options, Cancelled / Forfeited | shares | shares	(259)
Number of Options, Outstanding, Ending balance | shares | shares	586,874
Number of Options, Exercisable | shares | shares	586,874
Weighted-Average Exercise Price, Outstanding, Beginning balance | $ / shares | $ / shares	$ 4.90
Weighted-Average Exercise Price, Granted | $ / shares | $ / shares
Weighted-Average Exercise Price, Exercised | $ / shares | $ / shares
Weighted-Average Exercise Price, Cancelled / Forfeited | $ / shares | $ / shares	4.90
Weighted-Average Exercise Price, Outstanding, Ending balance | $ / shares | $ / shares	4.90
Weighted-Average Exercise Price, Exercisable | $ / shares | $ / shares	$ 4.90
Weighted-Average Remaining Contractual Term, Outstanding, Beginning	3 years 7 months 28 days
Weighted-Average Remaining Contractual Term, Outstanding, Ending	3 years 1 month 24 days
Weighted-Average Remaining Contractual Term, Exercisable	3 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding, Beginning | $ | $	$ 2,877
Aggregate Intrinsic Value, Outstanding, Ending | $ | $	2,876
Aggregate Intrinsic Value, Exercisable | $ | $	$ 2,876

Equity (Details 1)

Equity (Details 1)	6 Months Ended
	Jan. 31, 2020$ / sharesshares
Equity [Abstract]
Number of Non-vested Shares, Beginning Balance | shares	156,426
Number of Non-vested Shares, Granted | shares	20,863
Number of Non-vested Shares, Vested | shares	(14,144)
Number of Non-vested Shares, Cancelled / Forfeited | shares
Number of Non-vested Shares, Ending Balance | shares	163,145
Weighted- Average Grant- Date Fair Value, Beginning balance | $ / shares	$ 10.41
Weighted- Average Grant- Date Fair Value, Granted | $ / shares	20.49
Weighted- Average Grant- Date Fair Value, Vested | $ / shares	17.25
Weighted- Average Grant- Date Fair Value, Cancelled / Forfeited | $ / shares
Weighted- Average Grant- Date Fair Value, Ending balance | $ / shares	$ 11.91

Equity (Details Textual)

Equity (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Aug. 31, 2019USD ($)shares	Nov. 15, 2018USD ($)$ / shares	Jan. 31, 2020USD ($)Nonemployeedirectorsshares
Total unrecognized non-vested stock-based compensation			$ 1,500
Vesting expected term			2 years 4 months 24 days
Number of options, cancelled shares | shares			259
Numbet of non non-employee directors | Nonemployeedirectors			3
Class B common stock
Conversion of common stock		$ 15,000
Conversion of common stock price per share | $ / shares		$ 8.47
Debt instrument interest percent		6.00%
Common stock conversion term		3 years
Interest expense	$ 667,000
Conversion of common stock shares | shares	1,849,749
Restricted shares granted | shares			4,203
Fair value of restricted shares			$ 208,000

Leases (Details)

Leases (Details) $ in Thousands	Jan. 31, 2020USD ($)
2020	$ 1,604
2021	3,156
2022	3,046
2023	2,757
2024	2,693
Thereafter	4,153
Total Minimum Future Rental Income	17,409
Related Parties [Member]
2020	1,006
2021	2,041
2022	2,078
2023	2,117
2024	2,155
Thereafter	1,659
Total Minimum Future Rental Income	11,056
Other [Member]
2020	598
2021	1,115
2022	968
2023	640
2024	538
Thereafter	2,494
Total Minimum Future Rental Income	$ 6,353

Leases (Details Textual)

Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jan. 31, 2020	Jan. 31, 2020
Loss (Textual)
Net operating leases with initial term expiration dates		Dates ranging from 2021 to 2028.
Related party leases expire, description		The Company has related party leases that expire in April 2025 for (i) an aggregate of 88,631 square feet, which includes two parking spots per thousand square feet of space leased at 520 Broad Street, and (ii) 3,595 square feet in Israel.
Annual rent		$ 2,000
Related parties terminate leases, description		The related parties have the right to terminate the domestic leases upon four months' notice, and upon early termination will pay a termination penalty equal to 25% of the portion of the rent due over the course of the remaining term. A related party has the right to terminate the Israeli lease upon four months' notice. IDT has the right to lease an additional 50,000 square feet, in 25,000-foot increments, in the building located at 520 Broad Street on the same terms as their base lease, and other rights should 25,000 square feet or less remain available to lessees in the building. Upon expiration of the lease, related parties have the right to renew the leases for another five years.
Other income	$ 1,200	$ 2,400

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] $ in Thousands	Feb. 03, 2020USD ($)
Subsequent Events (Textual)
Revolving term loan, maximum borrowing capacity	$ 50,000
Rafael Pharmaceuticals [Member]
Subsequent Events (Textual)
Equity interest, percentage	37.50%
equity interest, percentage	37.50%
Remaining equity interest, percentage	0.25
Issued and outstanding, percentage	12.00%
Maturity date	Feb. 3, 2025
Mr. Jonas [Member]
Subsequent Events (Textual)
equity interest, percentage	37.50%